Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
スポンサーリンク
概要
- 論文の詳細を見る
- 2008-01-10
著者
-
FURUSE Junji
Division of Hapatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
-
ISHII Hiroshi
Division of Hapatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
-
NAKAJIMA Keiko
Bayer Yakuhin
-
Furuse Junji
Division Of Hepatobiliary And Pancreatic Medical Oncology National Cancer Center Hospital East
-
Nakachi Kohei
Division Of Hepatobiliary And Pancreatic Medical Oncology National Cancer Center Hospital East
-
Suzuki Eiichiro
Division Of Hepatobiliary And Pancreatic Medical Oncology National Cancer Center Hospital East
-
SHIMIZU Satoshi
Division of Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital East
-
Shimizu Satoshi
Division Of Hepatobiliary And Pancreatic Medical Oncology National Cancer Center Hospital East
-
Ishii Hiroshi
Division Of Hepatobiliary And Pancreatic Medical Oncology National Cancer Center Hospital East
-
ISHII Hiroshi
Division of AIDS Vaccine Development, Institute of Medical Science, University of Tokyo
関連論文
- 日本人におけるヒトSLC29A1の新規遺伝子多型の同定
- Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
- Decreased striatal D_2 receptor density associated with severe behavioral abnormality in Alzheimer's disease
- Cognitive function and frontal lobe atrophy in normal elderly adults : Implications for dementia not as aging-related disorders and the reserve hypothesis
- Executive dysfunction can explain word-list learning disability in very mild Alzheimer's disease : The Tajiri Project
- Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
- Major histocompatibility complex class I-restricted cytotoxic T lymphocyte responses during primary simian immunodeficiency virus infection in Burmese rhesus macaques